We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.Back to HealioLast week, Healio provided live coverage of Digestive Disease Week, the largest gathering of experts in gastroenterology, hepatology, endoscopy and gastrointestinal surgery.During one presentation, researchers reported that a rectal expulsion device may help predict whether patients with chronic constipation will experience improvements with pelvic floor physical therapy. It was the top story in gastroenterology last week.Source: Adobe StockThe second top story covered a debate at Digestive Disease Week on the optimal strategy for liver biopsy: percutaneous vs. endoscopic ultrasound.Read these and more top stories in gastroenterology below:Rectal expulsion device may predict outcomes in patients with chronic constipationAn investigational, point-of-care rectal expulsion device may help determine whether patients with chronic constipation will improve with pelvic floor physical therapy, according to data presented at Digestive Disease Week 2022. Read more.Debate: ‘Safety, adequacy, cost’ still favor percutaneous vs. endoscopic ultrasound biopsyAlthough percutaneous liver biopsy is still the “gold standard,” advances in techniques and increased use of endoscopic ultrasound-guided biopsy may soon change that dynamic, according to a debate. Read more.Additional doses of SARS-CoV-2 vaccine heighten antibody response in patients with IBDSeroconversion rates and antibody response significantly increased after a third dose of SARS-CoV-2 vaccine in patients with inflammatory bowel disease, according to a presenter. Read more.VIDEO: Oral S1P receptor modulator induces clinical remission in UCIn a Healio video exclusive, Marla C. Dubinsky, MD, discusses results from the ELEVATE UC trials, in which once daily etrasimod induced clinical remission in patients with ulcerative colitis. Read more.VIDEO: Mirikizumab induces, maintains clinical remission at 1 year in UC patientsPatients with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained clinical remission and improved bowel urgency severity at 1 year in the phase 3 LUCENT-2 study. Read more.We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.Back to Healio